Abstract
Breast cancer (BC) is the most common cancer affecting women in the United States and metastatic breast cancer is the leading cause of death. The role estradiol plays in ER-positive BC is well-documented, but the way it contributes to ER-negative BC remains unclear. In the present study, we utilized an experimental model of BC metastasis into lung by injecting ER-negative murine 4T1 cells into mice via the lateral tail vein. A 56 % metastasis occurrence rate following the injection of 5 × 103 cells was observed, thus this cell number was selected to study the potential stimulatory effect of estradiol on ER-negative BC metastasis. Female ovariectomized mice were randomized into estradiol and control groups with 16 mice per group, and estradiol pellets were implanted subcutaneously in the estradiol group. Results demonstrated that estradiol accelerated BC metastasis as indicated by bioluminescent imaging. In addition, estradiol enhanced metastatic tumor colony formation and increased the size of tumor nodules in the lungs, which were due, in part, to the increase in proliferative cells in the metastatic tumors. In vitro, estradiol increased the motility and invasion of 4T1 cells, and the stimulatory effect on cell motility was not blocked by ICI 182, 780, confirming that ER was not involved in the process. Results from the present study suggest that estradiol plays a role in ER-negative BC metastasis in whole animals.
Similar content being viewed by others
References
Jemal A et al (2008) Annual report to the nation on the status of cancer, 1975–2005, featuring trends in lung cancer, tobacco use, and tobacco control. J Natl Cancer Inst 100(23):1672–1694
Hagemeister FB Jr et al (1980) Causes of death in breast cancer: a clinicopathologic study. Cancer 46(1):162–167
Jemal A et al (2003) Cancer statistics, 2003. CA Cancer J Clin 53(1):5–26
Pavese JM, Farmer RL, Bergan RC (2010) Inhibition of cancer cell invasion and metastasis by genistein. Cancer Metastasis Rev 29(3):465–482
Rosen PR et al (1989) A long-term follow-up study of survival in stage I (T1N0M0) and stage II (T1N1M0) breast carcinoma. J Clin Oncol 7(3):355–366
Lee YT (1985) Patterns of metastasis and natural courses of breast carcinoma. Cancer Metastasis Rev 4(2):153–172
Horwitz KB (2008) The year in basic science: update of estrogen plus progestin therapy for menopausal hormone replacement implicating stem cells in the increased breast cancer risk. Mol Endocrinol 22(12):2743–2750
Ma H et al (2006) Reproductive factors and breast cancer risk according to joint estrogen and progesterone receptor status: a meta-analysis of epidemiological studies. Breast Cancer Res 8(4):R43
Clemons M, Goss P (2001) Estrogen and the risk of breast cancer. N Engl J Med 344(4):276–285
Kaaks R et al (2005) Postmenopausal serum androgens, oestrogens and breast cancer risk: the European prospective investigation into cancer and nutrition. Endocr Relat Cancer 12(4):1071–1082
Diaz LK, Sneige N (2005) Estrogen receptor analysis for breast cancer: current issues and keys to increasing testing accuracy. Adv Anat Pathol 12(1):10–19
Skliris GP et al (2008) Estrogen receptor alpha negative breast cancer patients: estrogen receptor beta as a therapeutic target. J Steroid Biochem Mol Biol 109(1–2):1–10
Fox EM, Davis RJ, Shupnik MA (2008) ERbeta in breast cancer–onlooker, passive player, or active protector? Steroids 73(11):1039–1051
Omoto Y et al (2003) Estrogen receptor (ER) beta1 and ERbetacx/beta2 inhibit ERalpha function differently in breast cancer cell line MCF7. Oncogene 22(32):5011–5020
Buteau-Lozano H et al (2002) Transcriptional regulation of vascular endothelial growth factor by estradiol and tamoxifen in breast cancer cells: a complex interplay between estrogen receptors alpha and beta. Cancer Res 62(17):4977–4984
Chang EC et al (2006) Impact of estrogen receptor beta on gene networks regulated by estrogen receptor alpha in breast cancer cells. Endocrinology 147(10):4831–4842
Matthews J et al (2006) Estrogen receptor (ER) beta modulates ERalpha-mediated transcriptional activation by altering the recruitment of c-Fos and c-Jun to estrogen-responsive promoters. Mol Endocrinol 20(3):534–543
Roger P et al (2001) Decreased expression of estrogen receptor beta protein in proliferative preinvasive mammary tumors. Cancer Res 61(6):2537–2541
Leygue E et al (1998) Altered estrogen receptor alpha and beta messenger RNA expression during human breast tumorigenesis. Cancer Res 58(15):3197–3201
Jarvinen TA et al (2000) Estrogen receptor beta is coexpressed with ERalpha and PR and associated with nodal status, grade, and proliferation rate in breast cancer. Am J Pathol 156(1):29–35
Fuqua SA et al (2003) Estrogen receptor beta protein in human breast cancer: correlation with clinical tumor parameters. Cancer Res 63(10):2434–2439
O’Neill PA et al (2004) Wild-type oestrogen receptor beta (ERbeta1) mRNA and protein expression in Tamoxifen-treated post-menopausal breast cancers. Br J Cancer 91(9):1694–1702
Platet N et al (2004) Estrogens and their receptors in breast cancer progression: a dual role in cancer proliferation and invasion. Crit Rev Oncol Hematol 51(1):55–67
Neven P et al (2002) Endocrine treatment and prevention of breast and gynaecological cancers. Eur J Cancer 38(Suppl 6):S1–S11
Vergote I et al (2000) The oestrogen receptor and its selective modulators in gynaecological and breast cancer. Eur J Cancer 36(Suppl 4):S1–S9
Hartman J, Strom A, Gustafsson JA (2009) Estrogen receptor beta in breast cancer–diagnostic and therapeutic implications. Steroids 74(8):635–641
Warner M, Gustafsson JA (2010) The role of estrogen receptor beta (ERbeta) in malignant diseases–a new potential target for antiproliferative drugs in prevention and treatment of cancer. Biochem Biophys Res Commun 396(1):63–66
Yue W et al (2010) Effects of estrogen on breast cancer development: role of estrogen receptor independent mechanisms. Int J Cancer 127(8):1748–1757
Acconcia F, Kumar R (2006) Signaling regulation of genomic and nongenomic functions of estrogen receptors. Cancer Lett 238(1):1–14
Bjornstrom L, Sjoberg M (2005) Mechanisms of estrogen receptor signaling: convergence of genomic and nongenomic actions on target genes. Mol Endocrinol 19(4):833–842
Early Breast Cancer Trialists’ Collaborative Group (1992) Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. 133 randomised trials involving 31,000 recurrences and 24,000 deaths among 75,000 women. Lancet 339(8784):1–15
Early Breast Cancer Trialists’ Collaborative Group (1992) Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. 133 randomised trials involving 31,000 recurrences and 24,000 deaths among 75,000 women. Lancet 339(8785):71–85
Gupta PB et al (2007) Systemic stromal effects of estrogen promote the growth of estrogen receptor-negative cancers. Cancer Res 67(5):2062–2071
Banka CL et al (2006) Estrogen induces lung metastasis through a host compartment-specific response. Cancer Res 66(7):3667–3672
Reeves PG, Nielsen FH, Fahey GC Jr (1993) AIN-93 purified diets for laboratory rodents: final report of the American Institute of Nutrition ad hoc writing committee on the reformulation of the AIN-76A rodent diet. J Nutr 123(11):1939–1951
Miller FR (1983) Tumor subpopulation interactions in metastasis. Invasion Metastasis 3(4):234–242
Miller FR, Miller BE, Heppner GH (1983) Characterization of metastatic heterogeneity among subpopulations of a single mouse mammary tumor: heterogeneity in phenotypic stability. Invasion Metastasis 3(1):22–31
Hong X et al (2009) EBAG9 inducing hyporesponsiveness of T cells promotes tumor growth and metastasis in 4T1 murine mammary carcinoma. Cancer Sci 100(5):961–969
Aslakson CJ, Miller FR (1992) Selective events in the metastatic process defined by analysis of the sequential dissemination of subpopulations of a mouse mammary tumor. Cancer Res 52(6):1399–1405
Pulaski BA, Ostrand-Rosenberg S (1998) Reduction of established spontaneous mammary carcinoma metastases following immunotherapy with major histocompatibility complex class II and B7.1 cell-based tumor vaccines. Cancer Res 58(7):1486–1493
Pulaski, B.A. and S. Ostrand-Rosenberg, Mouse 4T1 breast tumor model. Curr Protoc Immunol, 2001. Chapter 20: p. Unit-Uni2
Adams LS et al (2010) Blueberry phytochemicals inhibit growth and metastatic potential of MDA-MB-231 breast cancer cells through modulation of the phosphatidylinositol 3-kinase pathway. Cancer Res 70(9):3594–3605
Valster A et al (2005) Cell migration and invasion assays. Methods 37(2):208–215
Ju YH et al (2001) Physiological concentrations of dietary genistein dose-dependently stimulate growth of estrogen-dependent human breast cancer (MCF-7) tumors implanted in athymic nude mice. J Nutr 131(11):2957–2962
Ju YH et al (2006) Genistein stimulates growth of human breast cancer cells in a novel, postmenopausal animal model, with low plasma estradiol concentrations. Carcinogenesis 27(6):1292–1299
Hiraga T et al (2004) Zoledronic acid inhibits visceral metastases in the 4T1/luc mouse breast cancer model. Clin Cancer Res 10(13):4559–4567
Muller A et al (2001) Involvement of chemokine receptors in breast cancer metastasis. Nature 410(6824):50–56
Ju YH et al (2006) Effects of dietary daidzein and its metabolite, equol, at physiological concentrations on the growth of estrogen-dependent human breast cancer (MCF-7) tumors implanted in ovariectomized athymic mice. Carcinogenesis 27(4):856–863
Pike MC et al (1993) Estrogens, progestogens, normal breast cell proliferation, and breast cancer risk. Epidemiol Rev 15(1):17–35
Gottardis MM, Robinson SP, Jordan VC (1988) Estradiol-stimulated growth of MCF-7 tumors implanted in athymic mice: a model to study the tumoristatic action of tamoxifen. J Steroid Biochem 30(1–6):311–314
Alliende ME (2002) Mean versus individual hormonal profiles in the menstrual cycle. Fertil Steril 78(1):90–95
Kaaks R et al (2005) Serum sex steroids in premenopausal women and breast cancer risk within the European Prospective Investigation into Cancer and Nutrition (EPIC). J Natl Cancer Inst 97(10):755–765
Bockhorn M, Jain RK, Munn LL (2007) Active versus passive mechanisms in metastasis: do cancer cells crawl into vessels, or are they pushed? Lancet Oncol 8(5):444–448
Nogawa M et al (2005) Monitoring luciferase-labeled cancer cell growth and metastasis in different in vivo models. Cancer Lett 217(2):243–253
Uneda S et al (2009) Anti-endoglin monoclonal antibodies are effective for suppressing metastasis and the primary tumors by targeting tumor vasculature. Int J Cancer 125(6):1446–1453
Oviedo PJ et al (2011) Estradiol induces endothelial cell migration and proliferation through estrogen receptor-enhanced RhoA/ROCK pathway. Mol Cell Endocrinol 335(2):96–103
Acconcia F, Barnes CJ, Kumar R (2006) Estrogen and tamoxifen induce cytoskeletal remodeling and migration in endometrial cancer cells. Endocrinology 147(3):1203–1212
Sanchez AM et al (2010) Estrogen receptor-alpha promotes breast cancer cell motility and invasion via focal adhesion kinase and N-WASP. Mol Endocrinol 24(11):2114–2125
Kedrin D et al (2007) Cell motility and cytoskeletal regulation in invasion and metastasis. J Mammary Gland Biol Neoplasia 12(2–3):143–152
Giretti MS et al (2008) Extra-nuclear signalling of estrogen receptor to breast cancer cytoskeletal remodelling, migration and invasion. PLoS ONE 3(5):e2238
Zheng S et al (2011) 17beta-Estradiol enhances breast cancer cell motility and invasion via extra-nuclear activation of actin-binding protein ezrin. PLoS ONE 6(7):e22439
Chambers AF, Matrisian LM (1997) Changing views of the role of matrix metalloproteinases in metastasis. J Natl Cancer Inst 89(17):1260–1270
Nilsson UW, Garvin S, Dabrosin C (2007) MMP-2 and MMP-9 activity is regulated by estradiol and tamoxifen in cultured human breast cancer cells. Breast Cancer Res Treat 102(3):253–261
Migliaccio A et al (1996) Tyrosine kinase/p21ras/MAP-kinase pathway activation by estradiol-receptor complex in MCF-7 cells. EMBO J 15(6):1292–1300
Zhang Z et al (2004) The role of adapter protein Shc in estrogen non-genomic action. Steroids 69(8–9):523–529
Song RX et al (2004) The role of Shc and insulin-like growth factor 1 receptor in mediating the translocation of estrogen receptor alpha to the plasma membrane. Proc Natl Acad Sci U S A 101(7):2076–2081
Yang Z, Barnes CJ, Kumar R (2004) Human epidermal growth factor receptor 2 status modulates subcellular localization of and interaction with estrogen receptor alpha in breast cancer cells. Clin Cancer Res 10(11):3621–3628
Restall C et al (2009) A novel histone deacetylase inhibitor augments tamoxifen-mediated attenuation of breast carcinoma growth. Int J Cancer 125(2):483–487
Acknowledgement
This study was supported by the National Cancer Institute [CA77355 to W.G.H.]; the National Institute on Aging, the National Institute for Complementary and Alternative Medicine and the Office of Dietary Supplements, the Women’s Health Initiative [P01 AG024387 to W.G.H. and Y.H.J.]; and the National Institute for Complementary and Alternative Medicine, the Office of Dietary Supplements and the National Cancer Institute [P50AT006268 to W.G.H.]. Its contents are solely the responsibility of the authors and do not necessarily represent the official views of the NICAM, ODS, NCI or the National Institutes of Health.
Conflict of interests
None declared.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Yang, X., Belosay, A., Du, M. et al. Estradiol increases ER-negative breast cancer metastasis in an experimental model. Clin Exp Metastasis 30, 711–721 (2013). https://doi.org/10.1007/s10585-012-9559-0
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10585-012-9559-0